American Heart Journal
Volume 150, Issue 4 , Pages 659-665 , October 2005

Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial

  • Alejandro Barbagelata, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • Marcelo F. Di Carli, MD

      Affiliations

    • Brigham and Women Hospital, Boston, Mass
  • ,
  • Robert M. Califf, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
  • ,
  • Jyotsna Garg, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
  • ,
  • Yochai Birnbaum, MD

      Affiliations

    • University of Texas Medical Branch, Galveston, Tex
  • ,
  • Liliana Grinfeld, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • Raymond J. Gibbons, MD

      Affiliations

    • Mayo Clinic, Rochester, Minn
  • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
  • ,
  • Shaun G. Goodman, MD

      Affiliations

    • Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Canada
  • ,
  • Galen S. Wagner, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Corresponding Author InformationReprints not available from the authors.
  • ,
  • Kenneth W. Mahaffey, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
  • ,
  • for the AMISTAD Investigators

Received 21 May 2004 ,Accepted 13 October 2004.

References 

  1. Gibbons RJ, Christian TF, Hopfenspirger MR, et al. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention. J Am Coll Cardiol. 1994;24:616
  2. Marzullo P, Sambuceti G, Parodi O. The role of sestamibi scintigraphy in the radio isotopic assessment of myocardial viability. J Nucl Med. 1992;33:1925–1930
  3. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993;328:685–691
  4. Schaer GL, Spaccavento LJ, Browne KF, et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation. 1996;94:298–307
  5. Mahaffey KW, Puma JA, Barbagelata NA. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711–1720
  6. Clemmensen P, Grande P, Sauamaki K, et al. Effect of intravenous streptokinase on the relation between initial ST-predicted size and final QRS-estimated size of acute myocardial infarcts. J Am Coll Cardiol. 1990;16:1252–1257
  7. Sevilla DC, Wagner NB, Pieper KS, et al. Use of the 12-lead ECG to detect myocardial reperfusion and salvage during acute myocardial infarction. J Electrocardiol. 1992;25:281–286
  8. Clemmensen P, Ohman ME, Sevilla D, et al. Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. Am J Cardiol. 1992;70:1391–1396
  9. Bar FW, Volders PG, Hoppener P, et al. Development of ST-segment elevation and Q and R wave changes in acute myocardial infarction and the influence of thrombolytic therapy. Am J Cardiol. 1996;77:337–343
  10. Aldrich HR, Wagner NB, Boswick J, et al. Use of initial ST-segment deviation for prediction of final electrocardiographic size of acute myocardial infarct. Am J Cardiol. 1988;61:749–753
  11. Clemmensen P, Grande P, Aldrich HR, et al. Evaluation of formulas for estimating the final size of acute myocardial infarcts from quantitative ST-segment elevation on the initial standard 12-lead ECG. J Electrocardiol. 1991;24:77–83
  12. Hindman NB, Douglas DS, Widmann M, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size: V. Specificity and method of application of the complete system. Am J Cardiol. 1985;55:1485–1490
  13. Sevilla DC, Wagner NB, Pegues R, et al. Correlation of the complete version of the Selvester QRS scoring system with quantitative anatomic findings for multiple left ventricular myocardial infarcts. Am J Cardiol. 1992;69:465–469
  14. Willems JL, Willems RJ, Bijnens I, et al. Value of electrocardiographic scoring systems for the assessment of thrombolytic therapy in acute myocardial infarction. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. Eur Heart J. 1991;12:378–388
  15. Juergens CP, Fernandes C, Hasche E, et al. Electrocardiographic measurement of infarct size after thrombolytic therapy. J Am Coll Cardiol. 1996;1:617–624
  16. Tateishi S, Abe S, Yamashita T, et al. Use of the QRS scoring system in the early estimation of myocardial infarct following reperfusion. J Electrocardiol. 1997;30:315–322
  17. Christian TF, Clements IP, Behrenbeck T, et al. Limitations of the electrocardiogram in estimating infarction size following acute reperfusion therapy. Ann Intern Med. 1991;114:264–270
  18. Christian TF, Gibbons RJ, Clements IP, et al. Estimates of myocardium at risk and collateral flow in acute myocardial infarction using electrocardiographic indexes with comparison to radionuclide and angiographic measures. J Am Coll Cardiol. 1995;26:338–393
  19. De Sutter J, Van de Wiele C, Gheeraert P, et al. The Selvester 32-point QRS score for evaluation of myocardial infarct size after primary coronary angioplasty. Am J Cardiol. 1999;83:255–257
  20. Altehofer C, Kaiser HJ, Dorr R, et al. Fluorine-18-deoxiglucose PET for assessment of viable myocardium in perfusion defects in 99m Tc Mibi SPECT: a comparative study in patients with coronary artery disease. Eur J Nucl Med. 1992;19:334–342
  21. Sawada SG, Allman K, Muziki O, et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol. 1994;23:92–98
  22. Birnbaum Y, Wagner GS. The initial electrocardiographic pattern in acute myocardial infarction: correlation with infarct size. J Electrocardiol. 1999;32(Suppl.):122–128
  23. Temple RJ. A regulatory authority's opinion about surrogate end points. In:  Nimmo WS,  Tucker GT editor. Clinical measurement in drug evaluation. New York: Wiley; 1985;
  24. Topol EJ, Ellis SG, Callif RM, et al. Combined tissue type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. J Am Coll Cardiol. 1989;14:877–884
  25. Wall TC, Callif RM, Blankenship J, et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of the thrombolysis and angioplasty in myocardial infarction 9 trial. Circulation. 1994;90:114–120
  26. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS: a randomized factorial trial assessing early oral captoprill, oral mononitrate and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669–685
  27. Collaborative Organization for RheothRx Evaluation (CORE) . Effects of RheothRx on mortality, morbidity, left ventricular function and infarct size in patients with acute myocardial infarction. Circulation. 1997;96:192–201
  28. EMIP-FR Pilot Study Group. Free radicals, reperfusion and myocardial infarction therapy: European myocardial infarction project—free radicals pilot study. Eur Heart J (Suppl G). 1993;48–51
  29. Schaer GL, Spaccavento LJ, Browne KF, et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarct results of a randomized double-blind, placebo-controlled trial. Circulation. 1996;94:298–307

PII: S0002-8703(04)00761-6

doi: 10.1016/j.ahj.2004.10.014

American Heart Journal
Volume 150, Issue 4 , Pages 659-665 , October 2005